{
    "id": 1205,
    "fullName": "NTRK1 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NTRK1 mutant indicates an unspecified mutation in the NTRK1 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 4914,
        "geneSymbol": "NTRK1",
        "terms": [
            "NTRK1",
            "MTC",
            "p140-TrkA",
            "TRK",
            "Trk-A",
            "TRK1",
            "TRKA"
        ]
    },
    "variant": "mutant",
    "createDate": "07/30/2014",
    "updateDate": "08/01/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17314,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, LOXO-195 treatment resulted in an objective response rate of 45% (9/20) and stable disease in 30% (6/20) of adult and pediatric patients with advanced solid tumors harboring a NTRK mutation associated with resistance to TRK inhibitors in the context of NTRK fusions, who had progressed or were intolerant to prior Trk inhibitors (AACR Annual Meeting 2019, Abstract CT127; NCT03215511).",
            "molecularProfile": {
                "id": 32495,
                "profileName": "NTRK1 fusion NTRK1 mut"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15362,
                    "pubMedId": null,
                    "title": "Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/9845"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18041,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in rapid clinical improvement and a complete response 1 month after treatment in a patient with adenocarcinoma of unknown primary harboring MET amplification and a NTRK1 mutation (c.339-2 A>C), with a progression-free survival of 8.5 months and an overall survival of 10.0 months (PMID: 31213843).",
            "molecularProfile": {
                "id": 32950,
                "profileName": "MET amp NTRK1 mut"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 299,
                "name": "adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15970,
                    "pubMedId": 31213843,
                    "title": "Complete response to crizotinib in a metastatic adenocarcinoma of unknown primary harboring MET amplification and NTRK1 co-occurring mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31213843"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1229,
            "profileName": "NTRK1 mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32495,
            "profileName": "NTRK1 fusion NTRK1 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32950,
            "profileName": "MET amp NTRK1 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}